Agena
At AACR's annual meeting, industry observers discussed how FDA's stance on RUOs amid its push to regulate LDTs is putting the "double squeeze" on the lab industry.
At AACR's annual meeting, industry observers discussed how FDA's stance on RUOs amid its push to regulate LDTs is putting the "double squeeze" on the lab industry.